Last updated: September 24, 2026
NEXLIZET is a fixed-dose oral tablet combining bempedoic acid 180 mg and ezetimibe 10 mg. The product’s commercial opportunity for excipient suppliers and formulation partners is concentrated in direct-compression performance, two-API compatibility, supply-chain resilience, and differentiated reformulation. Its active ingredients are small molecules, so biosimilar competition is irrelevant; future competition will come from generic fixed-dose combinations, separate-component substitution, and alternative lipid-lowering therapies.
What is NEXLIZET and how is it formulated?
NEXLIZET is marketed by Esperion Therapeutics as a once-daily oral tablet for adults requiring additional low-density lipoprotein cholesterol reduction. The product combines:
| Attribute |
NEXLIZET |
| Active ingredients |
Bempedoic acid 180 mg; ezetimibe 10 mg |
| Dosage form |
Immediate-release film-coated tablet |
| Route |
Oral |
| Recommended dose |
One tablet once daily |
| U.S. approval |
February 26, 2020 |
| NDA |
NDA 211616 |
| Sponsor |
Esperion Therapeutics |
| Therapeutic class |
Lipid-lowering therapy |
| Primary commercial role |
Combination therapy for LDL-C reduction |
The approved product uses conventional small-molecule tablet technology rather than a controlled-release delivery system. Its formulation challenge is therefore less about extended release and more about obtaining robust content uniformity, disintegration, dissolution, mechanical strength, and chemical stability for two active pharmaceutical ingredients with different dose levels and physicochemical properties.
The FDA prescribing information identifies inactive ingredients that include common tablet excipients such as microcrystalline cellulose, crospovidone, hydroxypropyl cellulose, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate, and film-coating components. The exact formulation and grade selection remain commercially important because excipient functionality can affect manufacturability even when the qualitative ingredient list is unchanged (FDA, 2024a).
What excipient functions are most important in NEXLIZET?
The highest-value excipient requirements are linked to tablet compression, blend uniformity, dissolution, and manufacturing consistency.
| Formulation need |
Relevant excipient function |
Commercial opportunity |
| Uniform distribution of 10 mg ezetimibe |
Diluent and high-shear blending performance |
Co-processed fillers and engineered particle-size grades |
| Tablet strength |
Binder and compactability |
Low-force, high-tensile-strength excipients |
| Rapid drug release |
Superdisintegrant and wetting agent |
Crospovidone, sodium starch glycolate, surfactant systems |
| Flow through tablet equipment |
Glidant and optimized particle morphology |
Colloidal and precipitated silica grades |
| Lubrication |
Magnesium stearate or alternative lubricant |
Low-overlubrication systems |
| Chemical and physical stability |
Moisture and oxygen control |
Barrier packaging and low-moisture excipients |
| Scalable production |
Consistent bulk density and flow |
Direct-compression excipient platforms |
| Patient acceptability |
Film coating, swallowability, appearance |
Low-weight, fast-dissolving coating systems |
Direct-compression excipients
NEXLIZET is well positioned for direct-compression excipient innovation because the tablet contains a relatively high dose of bempedoic acid alongside a lower-dose ezetimibe component. A direct-compression diluent must accommodate segregation risk between particles with different densities, shapes, and surface properties.
Mannitol, microcrystalline cellulose, lactose-based systems, and co-processed fillers can compete on:
- Flowability
- Compactability
- Reduced segregation
- Low friability
- Lower lubricant sensitivity
- Improved dissolution consistency
A co-processed excipient combining a compressible cellulose component with a soluble filler could reduce the number of formulation variables. The commercial value would be greatest if the supplier can demonstrate equivalent or superior dissolution and content uniformity without changing the product’s release profile.
Disintegrants and wetting agents
Crospovidone is a likely performance driver for immediate tablet breakup. Sodium lauryl sulfate or another wetting agent can improve wetting of hydrophobic drug particles, but excessive surfactant can affect tablet strength, dissolution behavior, and gastrointestinal tolerability.
A supplier opportunity exists for low-use-level disintegration systems that preserve rapid release while reducing surfactant load. This is relevant to generic manufacturers seeking a simple formulation with a low risk of bioequivalence failure.
Lubrication
Magnesium stearate is widely used but can reduce tablet wettability and slow dissolution when overmixed. A formulation partner could create value through:
- Shorter lubrication time
- Lower lubricant concentration
- Alternative lubricants
- Narrower control of specific surface area
- In-line monitoring of blend lubrication
These changes are more likely to support manufacturing efficiency than to create independent product differentiation. They can still be commercially valuable in generic development because dissolution variability and scale-up failures increase approval risk.
What formulation patents protect NEXLIZET?
Public FDA labeling confirms the commercial formulation but does not, by itself, establish the scope of Esperion’s formulation patent rights. Patent protection must be assessed through the U.S. Patent and Trademark Office, FDA Orange Book, international patent registers, and litigation records.
The relevant intellectual-property categories are:
- Bempedoic acid compound and salt patents.
- Bempedoic acid formulation patents.
- Bempedoic acid and ezetimibe combination patents.
- Methods of reducing LDL cholesterol.
- Cardiovascular-risk-reduction methods.
- Manufacturing and crystallization processes.
- Formulation-specific patents covering excipient ratios, particle sizes, or dissolution performance.
An excipient substitution is not automatically outside the patent estate. A generic formulation may avoid a narrow excipient claim while still infringing a broader combination, dosage-form, process, or method-of-use claim. Conversely, a listed formulation patent may not cover every practical excipient alternative.
The Orange Book should be used to determine which patents are listed against NDA 211616, their statutory expiration dates, and any pediatric extensions. Patent expiration cannot be reliably inferred from the date of FDA approval or from the expiration date of a separate bempedoic acid or ezetimibe patent family (FDA, 2024b).
When does NEXLIZET lose regulatory exclusivity?
NEXLIZET received approval as a fixed-dose combination of previously known active ingredients. Its commercial exclusivity therefore differs from a new chemical entity product.
| Exclusivity category |
Relevance to NEXLIZET |
| New chemical entity exclusivity |
Generally not expected for a combination of previously approved active ingredients |
| Three-year clinical-investigation exclusivity |
Potentially relevant if the approval relied on qualifying new clinical investigations |
| Pediatric exclusivity |
Applies only if separately granted by FDA |
| Orphan exclusivity |
Not applicable to the broad LDL-lowering indication |
| Patent exclusivity |
Depends on listed patents, patent-term adjustment, and litigation outcomes |
The three-year exclusivity framework can block approval of an ANDA or 505(b)(2) application that relies on the protected change, even though it does not necessarily block all independent applications. The exact regulatory barrier depends on the approved labeling, the type of abbreviated application, and the exclusivity entry in FDA’s Orange Book.
What generic entry risks exist for NEXLIZET?
NEXLIZET faces several potential entry routes.
Fixed-dose combination ANDA
A generic manufacturer could submit an ANDA for bempedoic acid and ezetimibe tablets. The applicant would need to demonstrate pharmaceutical equivalence and bioequivalence, address listed patents, and certify to each applicable Orange Book patent.
A Paragraph IV certification could trigger patent litigation under the Hatch-Waxman Act. If the innovator files suit within the statutory period, FDA approval may be subject to a 30-month stay, unless the stay is shortened, terminated, or otherwise affected by court action (FDA, 2023).
Separate-component substitution
Separate bempedoic acid and ezetimibe products can compete with NEXLIZET even without a direct generic equivalent. This route can be commercially relevant because ezetimibe is widely available as a generic, while bempedoic acid products may have different levels of competition and reimbursement access.
The fixed-dose product retains advantages in pill burden, adherence, and prescription simplicity. Separate-component treatment retains advantages in dose flexibility and potentially lower acquisition cost.
505(b)(2) products
A sponsor could pursue a 505(b)(2) application for a modified dosage form, strength, or formulation. Such a product could target improved swallowability, reduced tablet size, altered excipient composition, or a different administration profile. The commercial case would require a clinically meaningful advantage or a clear manufacturing and reimbursement benefit.
Which excipient opportunities are commercially attractive?
The most credible opportunities are incremental rather than radical.
1. Generic-ready platform formulation
An excipient supplier can provide a package combining:
- Direct-compression filler
- Superdisintegrant
- Glidant
- Lubricant
- Film-coating system
The value proposition is a shorter development cycle, fewer formulation experiments, and more predictable scale-up. Such a platform is more attractive to generic manufacturers than an isolated replacement excipient.
2. Lactose-free or low-lactose positioning
If the reference formulation contains lactose or another dairy-derived component, a lactose-free generic formulation could address supplier qualification, patient preference, or manufacturing-site requirements. This would not create a new therapeutic indication, but it could simplify global sourcing and broaden manufacturing options.
The substitute must match tablet density, compactability, dissolution, and stability. Mannitol, microcrystalline cellulose, and co-processed polyols are possible development routes, subject to product-specific testing.
3. Smaller-tablet technology
A smaller tablet could improve swallowing and reduce packaging volume. The technical challenge is maintaining dose uniformity and mechanical strength while increasing drug loading. High-functionality fillers and dry granulation systems could support this objective.
4. Moisture-control systems
Bempedoic acid and ezetimibe combination products may require careful control of moisture, particle interactions, and coating integrity. Excipient suppliers can add value through low-moisture grades, desiccant-compatible packaging, and stability packages that reduce water activity without changing the drug product design.
5. Manufacturing localization
Regional manufacturers may seek excipients with multiple qualified sources, local regulatory support, and consistent compendial performance. Suppliers with manufacturing sites in the United States, Europe, India, and China can compete for generic NEXLIZET supply by reducing import dependence and qualification time.
What is the FDA regulatory status of NEXLIZET?
NEXLIZET is an FDA-approved prescription drug. The FDA label identifies the product as a fixed-dose combination of bempedoic acid and ezetimibe for LDL-C reduction. Bempedoic acid products have also been associated with cardiovascular-risk-reduction labeling developments, but the scope of any NEXLIZET-specific indication should be confirmed against the current FDA label rather than inferred from the label for NEXLETOL, the bempedoic-acid-only product (FDA, 2024a; FDA, 2024c).
Because the active ingredients are small molecules, NEXLIZET does not create a biosimilar pathway. Regulatory competition will use ANDA or 505(b)(2) mechanisms, not the abbreviated biologics license application pathway.
How does NEXLIZET compare with competing lipid-lowering products?
| Product |
Active ingredient(s) |
Main competitive issue |
| NEXLIZET |
Bempedoic acid plus ezetimibe |
Fixed-dose convenience and oral administration |
| NEXLETOL |
Bempedoic acid |
Dose flexibility and single-active-ingredient positioning |
| Generic ezetimibe |
Ezetimibe |
Low-cost LDL-C reduction |
| Statins |
Various statins |
First-line efficacy, cost, and broad generic availability |
| PCSK9 antibodies |
Evolocumab, alirocumab |
Strong LDL-C reduction but injectable administration |
| Inclisiran |
Inclisiran |
Infrequent dosing but specialty-product economics |
| Bile-acid sequestrants |
Various |
Older mechanism with tolerability and administration burdens |
NEXLIZET’s strongest commercial differentiation is the combination of oral bempedoic acid with generic-like ezetimibe in one tablet. Its principal risk is price pressure from separate-component therapy and future fixed-dose generic entry.
What is the revenue exposure and licensing opportunity?
Esperion has used commercialization partnerships and regional licensing arrangements for bempedoic acid products. The commercial importance of NEXLIZET depends on reimbursement, cardiovascular-outcome positioning, and the extent to which prescribers use the product instead of separate bempedoic acid and ezetimibe.
Esperion reported substantial growth in product revenue as its bempedoic acid portfolio expanded, but public company revenue reporting may combine NEXLETOL and NEXLIZET rather than disclose NEXLIZET separately. Excipient vendors should therefore evaluate opportunity through manufacturing volume, forecasted tablet demand, geographic launches, and generic-development activity rather than relying only on brand-level revenue disclosure (Esperion Therapeutics, 2024).
Potential licensing opportunities include:
- Regional commercialization rights
- Contract manufacturing of the fixed-dose tablet
- Generic development and launch licensing
- Co-processed excipient supply agreements
- Film-coating and packaging technology licenses
- Dual-source excipient qualification programs
Key Takeaways
- NEXLIZET is a once-daily immediate-release tablet containing bempedoic acid 180 mg and ezetimibe 10 mg.
- The strongest excipient opportunities involve direct compression, blend uniformity, rapid disintegration, lubrication control, and moisture management.
- Co-processed excipient platforms are more commercially attractive than single-ingredient substitutions.
- Generic competition can arise through a fixed-dose ANDA, separate-component substitution, or a 505(b)(2) product.
- NEXLIZET has no biosimilar risk because both active ingredients are small molecules.
- Orange Book listings, not the FDA label alone, determine the relevant patent barriers and expiration dates.
- Excipient differentiation is most likely to support generic development, manufacturing efficiency, tablet-size reduction, or supply-chain resilience rather than create a new therapeutic market.
FAQs
Can a generic NEXLIZET use different excipients?
Yes. An ANDA applicant can generally use different inactive ingredients if the proposed product meets pharmaceutical-equivalence, bioequivalence, quality, safety, and labeling requirements. The formulation must also avoid or lawfully address applicable patent claims.
Is NEXLIZET protected by an excipient patent?
The qualitative excipient list in the FDA label does not establish whether an excipient-specific patent protects the product. Patent scope must be determined from issued claims and current Orange Book listings.
Which excipient is most important for NEXLIZET bioequivalence?
No single excipient controls bioequivalence. The highest-risk variables are usually blend uniformity, wetting, disintegration, lubrication, particle-size distribution, and dissolution behavior for the two active ingredients.
Can a lactose-free NEXLIZET generic be developed?
A lactose-free formulation may be feasible if the substitute excipient system maintains tablet strength, content uniformity, dissolution, stability, and bioequivalence. The change would require product-specific development and regulatory documentation.
Is a smaller NEXLIZET tablet commercially viable?
Potentially. Smaller-tablet development could improve swallowing and reduce packaging costs, but it must preserve dose uniformity and mechanical performance at the high bempedoic-acid load.
References
-
Esperion Therapeutics, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2024a). Nexlizet prescribing information. Esperion Therapeutics.
-
U.S. Food and Drug Administration. (2024b). Patent and exclusivity information. https://www.fda.gov/drugs/development-approval-process-drugs/orange-book-data-files
-
U.S. Food and Drug Administration. (2024c). Nexletol prescribing information. Esperion Therapeutics.
